Aberdeen Group’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.7M Buy
1,237,401
+390,706
+46% +$5.05M 0.02% 531
2026
Q2
$11M Buy
846,695
+139,039
+20% +$1.57M 0.02% 577
2026
Q1
$7.42M Buy
+707,656
New +$10M 0.01% 637

Other funds holding AGMB

Aberdeen Group's AGMB Position: Q3 2026 in Review

Aberdeen Group increased its AgomAb Therapeutics NV (AGMB) stake by 46% in Q3 2026, buying an estimated $5.05M and bringing the position to 1,237,401 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #531.

Aberdeen Group first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Aberdeen Group held 1,237,401 shares of AgomAb Therapeutics NV worth $13.7M as of Q3 2026.
  • Aberdeen Group bought 390,706 AgomAb Therapeutics NV shares in Q3 2026, an estimated $5.05M.
  • AgomAb Therapeutics NV made up 0.02% of Aberdeen Group's portfolio in Q3 2026, its #531 holding.
  • Aberdeen Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.